Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs

European Journal of Pharmaceutical Sciences

Volumn 38, Issue 5, 2009, Pages 519-524

  Cermak, Rainer ^a   Wein, Silvia ^b   Wolffram, Siegfried ^b   Langguth, Peter ^c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Absorption; Bioavailability; Pharmacokinetic interaction; Quercetin; Simvastatin; Statins

Indexed keywords

QUERCETIN; SIMVASTATIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; SWINE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FLAVONOLS; FOOD-DRUG INTERACTIONS; MALE; QUERCETIN; SIMVASTATIN; SWINE;

EID: 70449524219     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.09.018     Document Type: Article

References (37)

1. Ader P., Wessmann S., and Wolffram S. Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic. Biol. Med. 28 (2000) 1056-1067
2. Alemdaroglu N.C., Dietz U., Wolffram S., Spahn-Langguth H., and Langguth P. Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability. Biopharm. Drug Dispos. 29 (2008) 335-348
3. Backman J.T., Kyrklund C., Kivistö K.T., Wang J.S., and Neuvonen P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68 (2000) 122-129
4. Bailey D.G., Dresser G.K., Leake B.F., and Kim R.B. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 81 (2007) 495-502
5. Bieger J., Cermak R., Blank R., de Boer V.C.J., Hollman P.C.H., Kamphues J., and Wolffram S. Tissue distribution of quercetin in pigs after long-term dietary supplementation. J. Nutr. 138 (2008) 1417-1420
6. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev. 56 (1998) 317-333
7. Cermak R., Landgraf S., and Wolffram S. The bioavailability of quercetin in pigs depends on the glycoside moiety and on dietary factors. J. Nutr. 133 (2003) 2802-2807
8. Cermak R., and Wolffram S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr. Drug Metab. 7 (2006) 729-744
9. Draganov D.I., Stetson P.L., Watson C.E., Billecke S.E., and La Du B.N. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 275 (2000) 33435-33442
10. Graf B.A., Milbury P.E., and Blumberg J.B. Flavonols, flavones, flavanones, and human health: epidemiological evidence. J. Med. Food 8 (2005) 281-290
11. Ha H.R., Chen J., Leuenberger P.M., Freiburghaus A.U., and Follath F. In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Eur. J. Clin. Pharmacol. 48 (1995) 367-371
12. Hertog M.G.L., Hollman P.C.H., Katan M.B., and Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr. Cancer 20 (1993) 21-29
13. Kantola T., Kivistö K.T., and Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 64 (1998) 177-182
14. Kaufman D.W., Kelly J.P., Rosenberg L., Anderson T.E., and Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287 (2002) 337-344
15. Kessler R.C., Davis R.B., Foster D.F., Van Rompay M.I., Walters E.E., Wilkey S.A., Kaptchuk T.J., and Eisenberg D.M. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann. Intern. Med. 135 (2001) 262-268
16. Kolars J.C., Schmiedlin-Ren P., Schuetz J.D., Fang C., and Watkins P.B. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90 (1992) 1871-1878
17. Kroon P.A., Clifford M.N., Crozier A., Day A.J., Donovan J.L., Manach C., and Williamson G. How should we assess the effects of exposure to dietary polyphenols in vitro. Am. J. Clin. Nutr. 80 (2004) 15-21
18. Middleton E., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 52 (2000) 673-751
19. Miniscalco A., Lundahl J., Regardh C.G., Edgar B., and Eriksson U.G. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharmacol. Exp. Ther. 261 (1992) 1195-1199
20. Morris M.E., and Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci. 78 (2006) 2116-2130
21. Neuvonen P.J., Backman J.T., and Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet. 47 (2008) 463-474
22. Neuvonen P.J., Niemi M., and Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80 (2006) 565-581
23. Ofer M., Wolffram S., Koggel A., Spahn-Langguth H., and Langguth P. Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT?. Eur. J. Pharm. Sci. 25 (2005) 263-271
24. Prueksaritanont T., Gorham L.M., Ma B., Liu L., Yu X., Zhao J.J., Slaughter D.E., Arison B.H., and Vyas K.P. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450S. Drug Metab. Dispos. 25 (1997) 1191-1199
25. Prueksaritanont T., Ma B., and Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol. 56 (2003) 120-124
26. Rafferty A.P., McGee H.B., Miller C.E., and Reyes M. Prevalence of complementary and alternative medicine use: state-specific estimates from the 2001 behavioral risk factor surveillance system. Am. J. Public Health 92 (2002) 1598-1600
27. Rahman A., Korzekwa K.R., Grogan J., Gonzalez F.J., and Harris J.W. Selective biotransformation of taxol to 6a-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54 (1994) 5543-5546
28. Rajnarayana K., Reddy M.S., and Krishna D.R. Diosmin pretreatment affects bioavailability of metronidazole. Eur. J. Clin. Pharmacol. 58 (2003) 803-807
29. Raucy J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos. 31 (2003) 533-539
30. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34 (2002) 83-448
31. Schubert W., Eriksson U., Edgar B., Cullberg G., and Hedner T. Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17b-estradiol. Eur. J. Drug Metab. Pharmacokinet. 20 (1995) 219-224
32. Tang B.K., and Kalow W. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. Eur. J. Clin. Pharmacol. 47 (1995) 449-451
33. Tubic-Grozdanis M., Hilfinger J.M., Amidon G.L., Kim J.S., Kijek P., Staubach P., and Langguth P. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm. Res. 25 (2008) 1591-1600
34. Vree T.B., Dammers E., Ulc I., Horkovics-Kovats S., Ryska M., and Merkx I. Variable plasma/liver and tissue esterase hydrolysis of simvastatin in healthy volunteers after a single oral dose. Clin. Drug Investig. 21 (2001) 643-652
35. Wang X., Wolkoff A.W., and Morris M.E. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab. Dispos. 33 (2005) 1666-1672
36. Williams D., and Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41 (2002) 343-370
37. Zuber R., Anzenbacherová E., and Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J. Cell. Mol. Med. 6 (2002) 189-198